In 2014 Alere received clearance from US FDA for the Alere i Influenza A&B, a test to detect and differentiate influenza A&B virus in less than 15 minutes, in Jan 2015, Alere received US CLIA waiver for the Alere i Influenza test.
In 2014 Alere received clearance from US FDA for the Alere i Influenza A&B, a rapid molecular point-of-care test to detect and differentiate Influenza A&B virus in less than 15 minutes. In Jan 2015, Alere received US CLIA waiver for the Alere i Influenza test.